Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus
| Autor: | M. Rosety, A. Garcia-Egido, Rocio Aranda, Maria J. Pedrosa, F. Gomez, J. J. B. Lopez-Saez, Jose L. Andrey, Jose L. Puerto |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Carbazoles Severity of Illness Index Propanolamines Internal medicine Diabetes mellitus Severity of illness medicine Bisoprolol Humans Prospective Studies Prospective cohort study Carvedilol Aged Heart Failure Ejection fraction business.industry Case-control study General Medicine Prognosis medicine.disease Endocrinology Diabetes Mellitus Type 2 Spain Case-Control Studies Heart failure Adrenergic alpha-1 Receptor Antagonists Cardiology Female business medicine.drug |
| Zdroj: | International Journal of Clinical Practice. 69:550-559 |
| ISSN: | 1368-5031 |
| Popis: | SummaryBackground The influence of beta-blocker therapy (bisoprolol or carvedilol) (bB) on the prognosis of heart failure (HF) patients with diabetes mellitus (DM) is uncertain. Aims To assess the effect of bB on the prognosis of HF patients with new-onset DM treated with a contemporary medical regime. Methods Prospective study of 5314 HF patients with previously unknown DM. Mean age was 71.8 ± 7.9 years, 53.0% were women, and 50.2% had HF with preserved ejection fraction (HFpEF). During a median follow-up of 56.9 ± 18.2 months, 68.9% of the patients died, 88.6% were hospitalised for HF, and 1519 (27.3%) developed DM (62.3% of them received bB, 947 patients). We propensity-matched 572 HF patients with DM on bB, with 572 HF patients with DM non-treated with bB. Results Beta-blocker therapy was associated with a decreased hazard risk (HR) of all-cause death [HR: 0.68, CI 95% (0.61–0.75)], mainly because of a reduced risk of death from cardiovascular causes [HR: 0.70 (0.64–0.77)] (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|